Pharmaceutical Processing | Alvotech Invests $250M in Biopharmaceuticals Pharmaceutical Processing Alvotech today announced plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies. Alvotech's current biosimilar assets include follow-on versions of leading monoclonal antibodies molecules ... Alvogen Pumping $250M into Developing Biosimilars, with New Iceland Plant Alvotech Invests $250 Million in Biopharmaceuticals |
